Development of anticancer gene vaccine interact with human papillomavirus oncoprotein inhibition.

Show simple item record

dc.contributor.author Ahn, WS en
dc.contributor.author Bae, SM en
dc.contributor.author Lee, HJ en
dc.contributor.author Kim, YW en
dc.contributor.author Lee, JM en
dc.contributor.author Namkoong, SE en
dc.contributor.author Kim, CK en
dc.contributor.author Kim, YW en
dc.contributor.author Jin, Hyun Sun en
dc.coverage.spatial United States en
dc.date.accessioned 2011-02-03T02:19:36Z en
dc.date.issued 2006-01 en
dc.identifier.citation Int J Gynecol Cancer 16(1):270-276 Jan 2006 en
dc.identifier.issn 1048-891X en
dc.identifier.uri http://hdl.handle.net/2292/6201 en
dc.description.abstract Adeno-associated virus (AAV) Rep 78 protein is known to inhibit the promoter site of several oncogenes and viral genes, including the human papillomavirus (HPV) type 16 E6 transforming genes. The biochemical studies of Rep 78 have been reported, but the effects of Rep 78 gene-mediated inhibition of HPV 16 E6 promoter activity on the various human cervical carcinoma cells have not been characterized. pEGFP-N1 vector, cloned by AAV-mediated Rep 78, is transfected into cervical carcinoma cells. Transfection efficiency of Rep 78 was approximately 30-60% different. Messenger RNA (mRNA) and protein expression of Rep 78 gene was significantly higher on day 1 of the transfection of Rep 78 DNA in CaSki cells, and DNA level of HPV 16 E6 was decreased on day 1 of the transfection. The growth of CaSki cervical cancer cells was only 10-15% inhibited by Rep 78, and the other cervical cells, HeLa, HeLaS3, HT3, and QGU, were unaffected by Rep 78 transfection. In spite of the high efficiency of Rep 78 gene transformation and expression rate, we could not show the significant growth inhibition in various cervical cancer cell lines. Taken together, long-term expression of Rep 78 strategy might be needed for cervical carcinoma gene therapy using AAV vector. en
dc.language eng en
dc.publisher IGCS en
dc.relation.ispartofseries Int J Gynecol Cancer en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/1048-891X/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.subject Base Sequence en
dc.subject Blotting, Northern en
dc.subject Blotting, Western en
dc.subject Cancer Vaccines en
dc.subject Cell Line, Tumor en
dc.subject Cell Transformation, Viral en
dc.subject Female en
dc.subject Gene Expression Regulation, Neoplastic en
dc.subject Genes, Viral en
dc.subject Humans en
dc.subject Immunohistochemistry en
dc.subject Molecular Sequence Data en
dc.subject Oncogene Proteins, Viral en
dc.subject Papillomaviridae en
dc.subject Papillomavirus Vaccines en
dc.subject Polymerase Chain Reaction en
dc.subject Probability en
dc.subject Sensitivity and Specificity en
dc.subject Transfection en
dc.subject Uterine Cervical Neoplasms en
dc.title Development of anticancer gene vaccine interact with human papillomavirus oncoprotein inhibition. en
dc.type Journal Article en
dc.identifier.doi 10.1111/j.1525-1438.2006.00343.x en
pubs.issue 1 en
pubs.begin-page 270 en
pubs.volume 16 en
dc.rights.holder Copyright: 2006 IGCS, International Journal of Gynecological Cancer en
dc.identifier.pmid 16445644 en
pubs.end-page 276 en
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Article en
pubs.elements-id 159633 en
dc.identifier.pii IJG343 en
pubs.record-created-at-source-date 2011-10-18 en
pubs.dimensions-id 16445644 en


Files in this item

There are no files associated with this item.

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics